Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Equity Average (2016 - 2025)

Historic Equity Average for Enanta Pharmaceuticals (ENTA) over the last 13 years, with Q3 2025 value amounting to $72.0 million.

  • Enanta Pharmaceuticals' Equity Average fell 4815.23% to $72.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.0 million, marking a year-over-year decrease of 4815.23%. This contributed to the annual value of $96.8 million for FY2025, which is 4399.32% down from last year.
  • Enanta Pharmaceuticals' Equity Average amounted to $72.0 million in Q3 2025, which was down 4815.23% from $86.4 million recorded in Q2 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Equity Average ranged from a high of $444.0 million in Q1 2021 and a low of $72.0 million during Q3 2025
  • In the last 5 years, Enanta Pharmaceuticals' Equity Average had a median value of $253.6 million in 2023 and averaged $255.7 million.
  • Its Equity Average has fluctuated over the past 5 years, first plummeted by 828.8% in 2021, then tumbled by 4815.23% in 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Equity Average (Quarter) stood at $391.9 million in 2021, then fell by 20.62% to $311.1 million in 2022, then plummeted by 34.32% to $204.3 million in 2023, then tumbled by 41.11% to $120.3 million in 2024, then plummeted by 40.16% to $72.0 million in 2025.
  • Its Equity Average was $72.0 million in Q3 2025, compared to $86.4 million in Q2 2025 and $102.7 million in Q1 2025.